CN116159018A - 一种新型外用溴莫尼定凝胶剂 - Google Patents
一种新型外用溴莫尼定凝胶剂 Download PDFInfo
- Publication number
- CN116159018A CN116159018A CN202310188180.XA CN202310188180A CN116159018A CN 116159018 A CN116159018 A CN 116159018A CN 202310188180 A CN202310188180 A CN 202310188180A CN 116159018 A CN116159018 A CN 116159018A
- Authority
- CN
- China
- Prior art keywords
- gel
- brimonidine
- oil
- carbomer
- tea tree
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229960003679 brimonidine Drugs 0.000 title claims abstract description 55
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 206010015150 Erythema Diseases 0.000 claims abstract description 27
- 229960001724 brimonidine tartrate Drugs 0.000 claims abstract description 27
- 231100000321 erythema Toxicity 0.000 claims abstract description 27
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 201000004700 rosacea Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000024883 vasodilation Effects 0.000 claims abstract description 7
- -1 hydroxyphenyl ester Chemical class 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 239000010677 tea tree oil Substances 0.000 claims description 44
- 229940111630 tea tree oil Drugs 0.000 claims description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 20
- 229920002125 Sokalan® Polymers 0.000 claims description 19
- 238000005303 weighing Methods 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 239000003906 humectant Substances 0.000 claims description 15
- 229960004063 propylene glycol Drugs 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 14
- 229960001631 carbomer Drugs 0.000 claims description 14
- 230000008961 swelling Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 239000004408 titanium dioxide Substances 0.000 claims description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229940031663 carbomer-974p Drugs 0.000 claims description 6
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000010659 mugwort oil Substances 0.000 claims description 5
- 239000003605 opacifier Substances 0.000 claims description 5
- 235000019501 Lemon oil Nutrition 0.000 claims description 4
- 235000019717 geranium oil Nutrition 0.000 claims description 4
- 239000010648 geranium oil Substances 0.000 claims description 4
- 239000010501 lemon oil Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 3
- 229940043234 carbomer-940 Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims 1
- 239000001524 citrus aurantium oil Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 9
- 241000220317 Rosa Species 0.000 abstract description 8
- 238000002425 crystallisation Methods 0.000 abstract description 8
- 230000008025 crystallization Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000003755 preservative agent Substances 0.000 abstract description 8
- 230000002335 preservative effect Effects 0.000 abstract description 8
- 208000020154 Acnes Diseases 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 80
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 22
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 18
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 18
- 229960002216 methylparaben Drugs 0.000 description 18
- 229960005150 glycerol Drugs 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 206010000496 acne Diseases 0.000 description 11
- 239000003349 gelling agent Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 206010037888 Rash pustular Diseases 0.000 description 7
- 241001303601 Rosacea Species 0.000 description 7
- 208000029561 pustule Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 241000366182 Melaleuca alternifolia Species 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000438 skin toxicity Toxicity 0.000 description 2
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 2
- DKZMSQCWKJPFLT-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21.OC(=O)[C@H](O)[C@@H](O)C(O)=O DKZMSQCWKJPFLT-LREBCSMRSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000011376 Leptospermum laevigatum Species 0.000 description 1
- 235000017865 Leptospermum laevigatum Nutrition 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 229940032978 brimonidine topical gel Drugs 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008252 pharmaceutical gel Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 231100000314 skin damage score Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000005412 xenoestrogen Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于医药技术领域，提供了一种新型外用的溴莫尼定凝胶剂以及在治疗轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮中的应用，该新型溴莫尼定凝胶剂用挥发油代替传统羟苯酯类防腐剂，不仅避免固体羟苯酯类防腐剂在凝胶剂中的析晶问题和规避羟苯酯类化合物对人体的潜在风险；而且加入挥发油能显著增加酒石酸溴莫尼定在减少玫瑰痤疮患者的红斑面积和缓解症状方面的疗效。该新型溴莫尼定凝胶剂制备工艺简单，易于工业化生产，具有较好的应用潜力。
Description
技术领域
本发明涉及医药技术领域，具体涉及一种含有挥发油的新型外用溴莫尼定凝胶剂和制备方法以及治疗轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮中的应用。
背景技术
酒石酸溴莫尼定(Brimonidine tartrate)，为5-溴-6-(2-咪唑双烯氨)喹噁啉L-酒石酸盐，结构式如下：
作为一种肾上腺素α2-受体激动剂，其作用于虹膜-睫状体α2-肾上腺素能受体，通过减少房水生成，达到降低眼压的作用，且副作用较小。临床上使用0.2％
及0.15％/>
酒石酸溴莫尼定滴眼液治疗开角型青光眼及高眼压症。近年来有研究发现溴莫尼定具有收缩血管的生理作用，2013年，FDA批准了Galderma公司的新产品
为浓度0.33％溴莫尼定(相当于5％酒石酸溴莫尼定)外用凝胶，通过作用于面部血管周围平滑肌，收缩血管，从而减轻患者面部红斑与水肿等症状。主要适用于红斑血管扩张型玫瑰痤疮。玫瑰痤疮是一种常发于面中部，主要累及面部皮下血管与毛囊皮脂腺的慢性炎症型皮肤病，以面部红色斑块，毛细血管扩张、丘疹、水肿等症状为主，通常伴有灼热，刺痛，瘙痒等症状。目前其病因及发病机制尚未明确，主要认为与免疫系统缺陷、神经血管舒缩功能异常及局部微生物感染等因素有关，同时，受紫外线、温度刺激、饮食、情绪等外部因素影响。玫瑰痤疮治愈困难，目前临床治疗的主要目的是减轻临床症状，减缓病情进展过程。对于玫瑰痤疮中轻症患者，常使用外用药物治疗，溴莫尼定凝胶具有见效快、副作用较低、使用方便等优点，但对丘疹、脓疱及其带来的皮肤损伤无明显作用(AnzengruberF，Czernielewski J，Conrad C，et al.Swiss S1 guideline for the treatment ofrosacea.J Eur Acad Dermatol Venereol.2017；31(11)：1775-91)。
凝胶剂(gels)系指药物与能形成凝胶的辅料制成溶液、混悬或乳状液型的稠厚液体或半固体制剂。上市的
凝胶剂处方组成主要包括药物，卡波姆，丙二醇和丙三醇、尼泊金甲酯或羟苯甲脂、二氧化钛、pH调节剂、水。目前已公开的溴莫尼定外用凝胶专利主要是Galderma公司的CN2011800508992，该专利公开了一种以羟苯甲酯作为主要防腐剂溴莫尼定凝胶剂，用以治疗轻、中度红斑型玫瑰痤疮。该专利主要解决凝胶剂存在的羟苯甲酯结晶防止微生物污染问题，但固体羟苯甲酯水溶性较低且结晶性受卡波姆浓度影响，在凝胶剂开封使用后，仍存在析晶的风险。此外，尽管羟苯甲酯已广泛用于口服和外用制剂的防腐剂，但近年来的研究表明羟苯酯类防腐剂长期反复使用仍具有许多潜在风险，在CTFA进行的一项皮肤毒性研究中，一种含有0.2％羟苯甲酯的产品配方被局部应用于白化家兔3个月，接受每日5.5mg/cm2的剂量，涂布于8.4％的体表面积，结果发现与对照组相比，含有羟苯甲酯的产品可引起持续性明显至中度红斑、轻度水肿和间歇性轻度脱屑(CTFA，1981b.Subchronic(three-month)dermal toxicity study inrabbit with product CN0028 containing methyl paraben.)。尤其值得注意的是，Darbre，P等人的研究还发现羟苯甲酯对MCF7乳腺癌细胞具有极强的雌激素活性，可能达到17-β-雌二醇的几千倍，说明大量使用添加有羟苯甲酯的制剂会提高女性乳腺癌风险。William H等人研究也发现羟苯甲酯的添加还会提高乳腺癌细胞的抗药性，阻碍患者化疗过程，更进一步加剧了大众对于羟苯甲酯大范围使用的担忧(Goodson W.H.et al.(2011)Activation of the mTOR pathwayby low levels of xenoestrogens in breast epithelial cells from high-riskwomen.Carcinogenesis，32，1724-1733)。
挥发油(Essential Oils)是指从香料植物中加工提取所得到的挥发性油状芳香物质的总称。天然植物挥发油安全无毒，对皮肤具有杀菌、抗炎、愈合、除臭、镇静、驱虫、柔润细腻皮肤等作用，挥发油在外用药品和化妆品中，不仅使用广泛，而且历史悠久。常用的抗菌活性较好的挥发油有茶树油、薰衣草油、艾草油、橙花油、柠檬油、天竺葵油等，茶树油为一种从澳大利亚本土植物互叶白千层叶中蒸馏提取而出的一种天然植物精油，为一种带有特征香气的无色至淡黄色液体。主要组成为1.8-桉叶素、α-松油烯及γ-松油烯等。γ-松油烯已被证明可以影响细菌细胞壁的生成，破坏细胞质膜，并抑制葡萄糖依赖性呼吸，故其在抗菌消炎方面起有独特的作用。Carson CF等人的研究发现其对金黄葡萄球菌的MIC90为0.5％(Carson CF，Hammer KA，Riley TV.Broth micro-dilution method fordetermining the susceptibility of Escherichia coli and Staphylococcusaureusto the essential oil of Melaleucaalternifolia(tea tree oil).Microbios 1995；82：181-5)，Banes-Marshall L等人的研究发现其对铜绿假单胞菌的MIC90小于2％(Banes-Marshall L，Cawley P，Phillips CA.In vitro activity of Melaleuca alternifolia(tea tree)oil against bacterial and Candida spp.isolates from clinicalspecimens.Br J Biomed Sci 2001；58：139-45.)，均表明其对常见致病微生物具有良好的抑制作用，具有作为天然防腐剂的潜质。同时，其在促进伤口愈合方面亦有相关研究，KerrJ等在一项针对100名患有慢性伤口的患者研究表明，外用茶树油混合制剂作为辅助治疗，伤口愈合速度超出预期，同时，炎症、疼痛及伤口不良气味也迅速减少(Kerr J.usingessential oils in wound care for the elderly.Aromatherapy Today 2002；23：14-9.)。此外，关于茶树油的相关药物毒理性研究表明，其安全性良好，作为外用制剂对皮肤无刺激与副作用，Saller R，Berger T，Reichling J等人的研究表明，使用白化兔模型作为对象研究其急性真皮LD50数据时，将5.0g/kg.BW100％茶树油涂抹于白化兔皮肤，并保持2g/kg.BW 24h，实验对象无毒性迹象；在普通家兔皮肤上使用25％石蜡茶树油擦剂进行30天的皮肤刺激性试验，没有产生明显的刺激(Saller R，Berger T，Reichling J，etal.Pharmaceutical and medicinal aspects of Australian tea treeoil.Phytomedicine 1998；5：489-95.)。而羟苯甲酯大鼠真皮LD50约为500-1200mg/kg.EW，毒性远大于茶树油。薰衣草油、艾草油、橙花油、柠檬油、天竺葵油等对金黄色葡萄球菌、绿脓杆菌、白色念珠菌也都有显著的抑制作用。
针对溴莫尼定凝胶剂中羟苯甲酯防腐剂带来的上述风险问题，本专利提供一种含有抗菌作用挥发油的、无羟苯甲酯的外用酒石酸溴莫尼定凝胶剂以及在治疗轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮中的应用。研究结果令人高兴的是发现挥发油能显著增加酒石酸溴莫尼定在缓解玫瑰痤疮患者的红斑、丘疹的面积和症状方面的疗效，具有良好的应用前景。
发明内容
本发明的目的是能够提供一种含有抗菌作用挥发油的、无羟苯甲酯的外用酒石酸溴莫尼定凝胶剂以及在治疗轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮中的应用。
所述外用溴莫尼定凝胶剂由以下重量份的物质组成：酒石酸溴莫尼定，0.03-6.6％(w/w)，挥发油1-30％(w/w)，胶凝剂0.5-2％(w/w)，保湿剂4.5-15％(w/w)，物理遮光剂0.05-0.5％(w/w)，pH调节剂0.5-2.5％，纯化水46-90％。作为本发明的一种优选，包含以下重量比的物质：酒石酸溴莫尼定∶挥发油∶胶凝剂∶保湿剂∶物理遮盖剂∶pH调节剂∶纯化水＝(0.2-0.8％)∶(5-20％)∶(0.8-1.5％)∶(7-12％)∶(0.05-0.1％)∶(0.5-1％)∶(65-86％)。
所述外用溴莫尼定凝胶剂的pH为5.5-8.0；pH优选为6.5-7.5。pH检测方法为：取样品0.5g，加入蒸馏水及无水甲醇各25ml，搅拌使其充分溶解后用pH剂测定。
所述的外用溴莫尼定凝胶剂中，挥发油为天然植物经过提取纯化得到的且具有抗菌活性的提取物。挥发油选自薰衣草油、茶树油、艾草油、橙花油、柠檬油、天竺葵油中的一种或多种；作为本发明的优选，挥发油优选茶树油。本发明的进一步优选，茶树油添加量为10％。
所述的外用溴莫尼定凝胶剂中，胶凝剂选自卡波姆934P、卡波姆940、卡波姆941、卡波姆974P、甲基纤维素、羟丙基纤维素、羟丙甲基纤维素、羧甲基纤维素钠中的一种或多神，优选卡波姆974P；保湿剂选自丙二醇、丙三醇、丁二醇、聚乙二醇、聚丙二醇和山梨醇口的一种或几种；物理遮光剂选自二氧化钛、纳米二氧化钛、氧化锌和纳米氧化锌中的一种或几种；pH调节剂选自氢氧化钠、氢氧化钾、三乙醇胺中的一种或几种，优选氢氧化钠。
所述的外用溴莫尼定凝胶剂，具体制备方法如下：精密称取处方量胶凝剂加入适量纯水，溶胀12h备用。精密称取处方量酒石酸溴莫尼定、挥发油、保湿剂、物理遮盖剂，加入到溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，用1.5M氢氧化钠溶液调节混合物至适宜pH，最后加入适量纯水至足量，恃续搅拌至成品呈淡黄绿色质地均一凝胶，即得。
所述的外用溴莫尼定凝胶剂，其特征在于：适用局部给药，治疗包括但不限于轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮。
新型外用溴莫尼定凝胶剂的有益效果：(1)以挥发油代替羟苯甲酯作为制剂抑菌剂，避免了羟苯酯类防腐剂相关副作用及储存、使用过程中的析晶风险。(2)挥发油能显著增加溴莫尼定在缓解玫瑰痤疮患者的红斑、丘疹的症状方面的疗效(3)挥发油对皮肤具有杀菌、抗炎作用，有利于弥补了溴莫尼定凝胶制剂在应对细菌、毛囊虫感染导致的玫瑰痤疮效果不佳的缺点；挥发油能促进伤口愈合，有利于对玫瑰痤疮导致的脓疱，丘疹等症状的治疗。(4)茶树油等挥发油为植物天然提取成分，可进一步降低制剂对皮肤的刺激性，安全性高。(5)处方工艺简单，成本较低，适宜工业化生产。
附图说明
图1是胶凝剂浓度对溴莫尼定凝胶剂体外释放的影响。
图2是组合保湿剂浓度对溴莫尼定凝胶剂体外释放的影响。
图3是含与不含茶树油的溴莫尼定凝胶剂的体外释放曲线的比较。
图4含茶树油的溴莫尼定凝胶剂治疗后红斑面积减少量的比较(*P＜0.05，**P＜0.01)
图5含茶树油的溴莫尼定凝胶剂的药效评分(*P＜0.05，**P＜0.01)
具体实施方式
下面结合具体实例对本申请做出详细说明。实施例中提及药物、试剂、动物等均为市售产品。
实施例1制备不同浓度胶凝剂的溴莫尼定凝胶剂。
分别精密称取卡波姆974P 0.5g、1.0g、1.5g，加入约60ml纯水，溶胀12h备用；各组再加入酒石酸溴莫尼定0.5g，二氧化钛0.05g，甘油5g，丙二醇5g，500r/min搅拌15min至混合完全，再将转速增加至800r/min，用1.5M氢氧化钠溶液滴加至pH＝7，最后加入适量纯水将样品总重补至100g即得。
实施例2制备不同浓度保湿剂组合(甘油、丙二醇)的溴莫尼定凝胶剂。
精密称取1.0g卡波姆974P，加入约60ml纯水，溶胀12h备用；精密称取酒石酸溴莫尼定0.5g，二氧化钛0.05g，分别加入低浓度保湿剂组合(甘油3.5g，丙二醇3.5g)、中浓度保湿剂组合(甘油5.0g，丙二醇5.0g)及高浓度保湿剂组合(甘油6.5g，丙二醇6.5g)于溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝7，最后加入适量纯水将样品总重补至100g即得。
实施例3制备溴莫尼定凝胶剂。
精密称取1.0g卡波姆974P，加入约60ml纯水，溶胀12h备用；精密称取酒石酸溴莫尼定0.5g，二氧化钛0.05g，甘油5g，丙二醇5g，加入到溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝7，最后加入适量纯水将样品总重补至100g即得。
实施例4制备不同浓度茶树油的溴莫尼定凝胶剂
精密称取1.0g卡波姆974P，加入约60ml纯水，溶胀12h备用；加入酒石酸溴莫尼定0.5g，二氧化钛0.05g，甘油5g，丙二醇5g，分别称取茶树油1g，5g，10g，20g，30g，加入到卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝7，最后加入适量纯水将样品总重补至100g即得。
实施例5制备不同浓度茶树油的凝胶剂.
精密称取1.0g卡波姆974P，加入约60ml纯水，溶胀12h备用；加入二氧化钛0.05g，甘油5g，丙二醇5g，分别称取茶树油5g、10g、20g，加入到卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝7，最后加入适量纯水将样品总重补至100g，即得。
实施例6制备含艾草油的酒石酸溴莫尼定凝胶剂。
精密称取1.0g卡波姆940，加入约60ml纯水，溶胀12h备用；精密称取酒石酸溴莫尼定0.6g，艾草油10g，二氧化钛0.08g，甘油5g，丙二醇5g，加入到溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝6.90，最后加入适量纯水将样品总重补至100g。即得。
实施例7制备含薰衣草油的酒石酸溴莫尼定凝胶剂。
精密称取1.0g卡波姆940，加入约60ml纯水，溶胀12h备用；精密称取酒石酸溴莫尼定0.7g薰衣草油15g，二氧化钛0.1g，甘油5g，丙二醇5g，加入到溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，缓慢滴入1.5M氢氧化钠溶液至pH＝7.18，最后加入适量纯水将样品总重补至100g，即得。
实施例8药物凝胶剂体外释放试验
以Franz立体扩散池作为凝胶释药装置，有效扩散面积约为0.786cm2。选择0.45μm的PVDF微孔滤膜作为透过膜，安装好扩散池后，接收池中注满PBS缓冲溶液(pH＝7.4)，在给药池中加入1ml凝胶样品，保证接收池与给药池间无气泡滞留。将装置置于磁力搅拌器上，接通32℃恒温循环水，分别于30min，1h，2h，4h，6h，12h，24h取出1ml接受液(同时补充1ml等温PBS缓冲液)，过滤后滤液HPLC分析，测定溴莫尼定浓度，计算累积释放量。
(1)考察胶凝剂用量对溴莫尼定凝胶剂影响。
取实施例1的不同浓度胶凝剂的溴莫尼定凝胶剂，进行上述的体外释放试验，结果见图1。图1表明低浓度胶凝剂释放度最好，但在0.5％浓度下配制样品呈粘稠液体，测得其粘度仅72cP，达不到凝胶要求，故凝胶剂选用浓度即1.0％胶凝剂，其样品粘度为1200cP，符合凝胶要求。
(2)考察保湿剂用量对溴莫尼定凝胶剂影响。
实施例2中所配制样品作为实验对象，进行上述的体外释放试验，结果图2，图2可看出，中浓度保湿剂组合(甘油5g、丙二醇5g)配制的凝胶释放性能最好，故凝胶中保湿剂组合选为甘油5g、丙二醇5g。
(3)比较含与不含茶树油的溴莫尼定凝胶的体外释放度。
以实施例3和实施例4中茶树油浓度为10％的溴莫尼定凝胶剂进行释放度试验，结果见图3，图3表明添加茶树油有利于凝胶中溴莫尼定的释放。
实施例9含茶树油的溴莫尼定凝胶剂的相容性初步研究
取实施例4中茶树油浓度为10％的酒石酸溴莫尼定凝胶剂10g置于铝塑管包装中，密时置于40℃恒温稳定箱中，分别于第0、5、10天取样测定溴莫尼定浓度，观察外观。结果见表1.
表1含茶树油(10％)的酒石酸溴莫尼定凝胶剂相容性实验结果(n＝3)
| 时间/d | 外观 | 重量/g | pH | 含量％ | 外观 |
| 0 | 黄绿色均匀凝胶 | 10.03±0.02 | 6.99±0.04 | 0.491±0.21 | 均匀，无结晶 |
| 5 | 黄绿色均匀凝胶 | 9.81±0.04 | 7.03±0.08 | 0.494±0.14 | 均匀，无结晶 |
| 10 | 黄绿色均匀凝胶 | 9.79±0.06 | 7.01±0.13 | 0.503±0.41 | 均匀，无结晶 |
上述结果表明，添加10％茶树油对凝胶剂中溴莫尼定含量、pH和外观无明显影响，说明凝胶剂中茶树油与溴莫尼定具有较好的相容性。
实施例10凝胶剂的药效学评价
(1)LL-37抗菌肽诱导小鼠玫瑰痤疮模型的建立与治疗
小鼠先在独立通气笼中饲养48h，降低应激反应。在实验前24h用剃毛刀剃除小鼠背部毛发。将小鼠随机分为A(空白对照组)、B(造模组)、C(实施例5低浓度茶树油凝胶组)、D(实施例5中浓度茶树油凝胶组)、E(实施例6高浓度茶树油凝胶组)、F(实施例3溴莫尼定凝胶组)、G(实施例4低浓度茶树油的溴莫尼定凝胶组)、H(实施例1中浓度茶树油的溴莫尼定凝胶组)、I(实施例1高浓度茶树油的溴莫尼定凝胶组)，每组6只。
小鼠背部中央位置选出直径1cm的圆形区域作为受试部位。每12h对B、C、D、E、F、G、H、I组小鼠背部受试区域进行50μl LL-37溶液皮下注射，至形成真皮泡和红斑。共进行6次，A组在相同位置以相同频率皮下注射配置LL-37溶液用的注射用水。C、D、E、F、G、H、I组在第三次注射LL-37后，分别外用凝胶样品各0.5g进行治疗，每日两次，连续3天。
(2)结果
使用相机对第一次凝胶治疗前和凝胶最后一次给药后24h的患处进行拍照，并使用imageJ软件量取各实验小鼠患处红斑总面积，并计算红斑面积减少量，结果见表1和图4。
同时在最后一次给药治疗后24h对小鼠受试区域玫瑰痤疮红斑进行皮肤损伤评分，参照皮肤科疾病临床评分表，按照1-5分(5分为最高)对皮损程度，红斑扩散程度、水肿脓疱情况等指标对各实验对象玫瑰痤疮症状进行量化分析。并按照药效评分＝红斑面积减少量/(0.2*红斑扩散评分+0.4*皮损评分+0.4*水肿脓疱评分)，计算药效分数，评分数值越大代表治疗效果越好。结果见表1及图5。
表1凝胶治疗前、后红斑面积的比较
#与B组数据比较P＜0.05，##与B组数据比较P＜0.01；*与F组数据比较P＜0.05，**与F组数据比较P＜0.01；☆与G组数据比较P＜0.05，☆☆与G组数据比较P＜0.01.
表1和图4表明：治疗前除对照组(A组)外各组都形成明显的玫瑰痤疮样红斑，表明造模成功。治疗最后一次给药后24时各给药组(C至I组)小鼠患处玫瑰痤疮样红斑面积均有所减轻，从红斑面积减少量Δ值来看，与B组(造模组)Δ值相比各给药组(C-I组)的Δ值均有大幅度增加(P＜0.01)，表明茶树油凝胶、酒石酸溴莫尼定凝胶和含茶树油的酒石酸溴莫尼定凝胶均可显著减少小鼠受试部位红斑面积。与F组(溴莫尼定凝胶组)的Δ值比较，尽管三组茶树油凝胶(C、D、E组)的Δ值有一定增加，且呈现剂量-效应依赖性，但仅高剂量茶树油凝胶组(E组)Δ值与F组Δ值的差异具有统计学显著性(P＜0.05)；令人感兴趣的是，三组含茶树油的溴莫尼定凝胶组(G、H、I组)Δ值较F组Δ值有较大增加，其中H组和I组的Δ值与F组Δ值相比均具有极显著性差异(P＜0.01)，但H组和I组的Δ值相似，两者之间无显著性差异(P＞0.05)，表明茶树油添加量达到10％及以上时，茶树油-酒石酸溴莫尼定凝胶对红斑面积的减低效果最好。
从药效评分数据来看(见表1和图5)，给药各组(C-I组)药效分数与B组(造模组)相比均有较大提高(P＜0.01)，说明茶树油凝胶、溴莫尼定凝胶和含茶树油的溴莫尼定凝胶均可有效减轻小鼠受试部位总体症状。D组、E组的药效评分优于F组(P＜0.01)，说明茶树油单独治疗皮损、水肿、脓疱等症状的效果好于溴莫尼定。H组、I组药效数据最大，治疗效果最好，且与F组比较差异极显著(P＜0.01)，H组和I组不仅红斑面积大幅缩小，而且症状减轻更为明显，皮损部位基本愈合，疗效明显优于溴莫尼定凝胶，表明添加茶树油后能显著提高溴莫尼定对红斑、皮损、水肿、脓疱等玫瑰痤疮常见症状的疗效。
以上对本发明的具体实施例进行了详细描述，但只是作为范例，本发明并不限制于以上描述的具体实施例。因此，在不脱离本发明的精神和范围下所作的均等变换和修改，都应涵盖在本发明的范围内。
Claims (5)
1.一种新型外用溴莫尼定凝胶剂，其特征在于包含以下重量比的物质：酒石酸溴莫尼定0.03-6.6％(w/w)，挥发油1-30％(w/w)，胶凝剂0.5-2％(w/w)，保湿剂4.5-15％(w/w)，物理遮光剂0.05-0.5％(w/w)，pH调节剂0.5-2.5％(w/w)，纯水46-90％(w/w)；凝胶剂的pH为5.5-8.0。
2.根据权利要求1中所述的新型外用溴莫尼定凝胶剂，其特征在于所述挥发油为天然植物经过提取纯化得到的且具有抗菌活性的提取物。
3.根据权利要求1所述的新型外用溴莫尼定凝胶剂，其特征在于，挥发油选自薰衣草油、茶树油、艾草油、橙花油、柠檬油、天竺葵油中的一种或多种；胶凝剂选自卡波姆934P、卡波姆940、卡波姆941、卡波姆974P、甲基纤维素、羟丙基纤维素、羟丙甲基纤维素、羧甲基纤维素钠中的一种或多种；保湿剂选自丙二醇、丙三醇、丁二醇、聚乙二醇、聚丙二醇、山梨醇中的一种或几种；物理遮光剂选自二氧化钛、纳米二氧化钛、氧化锌和纳米氧化锌中的一种或几种；pH调节剂选自氢氧化钠、氢氧化钾、三乙醇胺中的一种或几种。
4.根据权利要求1中所述的新型外用溴莫尼定凝胶剂，其特征在于通过以下方法制备得到：精密称取处方量胶凝剂加入适量纯水，溶胀12h备用。精密称取处方量酒石酸溴莫尼定、挥发油、保湿剂、物理遮光剂，加入到溶胀完成的卡波姆溶液中，500r/min搅拌15min至混合完全，再将转速增加至800r/min，用1.5M氢氧化钠溶液调节pH，最后加入适量纯水至足量，持续搅拌至成品呈淡黄绿色质地均一凝胶，即得。
5.权利要求1-3中任一项所述的新型外用溴莫尼定凝胶剂，在制备治疗轻、中度红斑血管扩张型及丘疹脓疱型玫瑰痤疮的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310188180.XA CN116159018A (zh) | 2023-03-01 | 2023-03-01 | 一种新型外用溴莫尼定凝胶剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310188180.XA CN116159018A (zh) | 2023-03-01 | 2023-03-01 | 一种新型外用溴莫尼定凝胶剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116159018A true CN116159018A (zh) | 2023-05-26 |
Family
ID=86421756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310188180.XA Pending CN116159018A (zh) | 2023-03-01 | 2023-03-01 | 一种新型外用溴莫尼定凝胶剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116159018A (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163725B1 (en) * | 2010-10-21 | 2012-04-24 | Galderma R&D SNC | Gel compositions and methods of use |
| CN103140217A (zh) * | 2010-08-06 | 2013-06-05 | 盖尔德马研究及发展公司 | 用于治疗或预防皮肤病的化合物的组合 |
| CN103298451A (zh) * | 2010-10-21 | 2013-09-11 | 高德美国际公司 | 溴莫尼定凝胶剂组合物及其使用方法 |
| CN103313700A (zh) * | 2010-10-21 | 2013-09-18 | 高德美国际公司 | 外用凝胶剂组合物 |
| CN103550138A (zh) * | 2013-10-29 | 2014-02-05 | 中国药科大学 | 一种索拉非尼有机凝胶及其制备方法 |
| CN104666239A (zh) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | 酒石酸溴莫尼定凝胶及其制备方法 |
| CN107106571A (zh) * | 2014-12-12 | 2017-08-29 | 兴和株式会社 | 新型水性组合物 |
| CN109966245A (zh) * | 2019-04-03 | 2019-07-05 | 浙江省医学科学院 | 一种酒石酸溴莫尼定结冷胶型原位凝胶滴眼液及制备方法 |
-
2023
- 2023-03-01 CN CN202310188180.XA patent/CN116159018A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103140217A (zh) * | 2010-08-06 | 2013-06-05 | 盖尔德马研究及发展公司 | 用于治疗或预防皮肤病的化合物的组合 |
| US8163725B1 (en) * | 2010-10-21 | 2012-04-24 | Galderma R&D SNC | Gel compositions and methods of use |
| CN103298451A (zh) * | 2010-10-21 | 2013-09-11 | 高德美国际公司 | 溴莫尼定凝胶剂组合物及其使用方法 |
| CN103313700A (zh) * | 2010-10-21 | 2013-09-18 | 高德美国际公司 | 外用凝胶剂组合物 |
| CN103550138A (zh) * | 2013-10-29 | 2014-02-05 | 中国药科大学 | 一种索拉非尼有机凝胶及其制备方法 |
| CN104666239A (zh) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | 酒石酸溴莫尼定凝胶及其制备方法 |
| CN107106571A (zh) * | 2014-12-12 | 2017-08-29 | 兴和株式会社 | 新型水性组合物 |
| CN109966245A (zh) * | 2019-04-03 | 2019-07-05 | 浙江省医学科学院 | 一种酒石酸溴莫尼定结冷胶型原位凝胶滴眼液及制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 张文燕等: "酒石酸溴莫尼定凝胶抑菌效力检查方法研究", 《天津药学》, vol. 32, no. 2, pages 17 - 22 * |
| 邓仁远等: "痤疮的治疗进展", 《临床医药文献杂志》, vol. 5, no. 88, pages 197 - 198 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190037229A (ko) | 상승효과적 항진균 조성물 및 그의 방법 | |
| US20120264818A1 (en) | Topical Compositions with Cannabis Extracts | |
| CN109745261B (zh) | 一种头皮护理液及其制备方法 | |
| CA2835874C (en) | A topical formulation for treatment of hyperkeratotic skin | |
| EP0592569A1 (en) | Composition and method for transdermal delivery of diclofenac | |
| RU2370265C1 (ru) | Гель, обладающий противовоспалительным и противоаллергическим действием | |
| EP2191828A1 (en) | Antifungal pharmaceutical composition | |
| AU2019210703B2 (en) | Cannabinoid dosing regime for dermatitis and inflammatory skin conditions | |
| US20130274321A1 (en) | Topical Compositions with Cannabis Extracts | |
| KR20140053226A (ko) | 백단향 오일 및 피부 질환에 관련된 이의 용도 | |
| EP3677265A1 (en) | Composition for preventing or treating sleep disorders | |
| CN107670027B (zh) | 治疗皮肤病况的组合物和方法 | |
| EP3842030A2 (en) | Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair | |
| Kintoko et al. | The effectivity of ethanolic extract of binahong leaves (Anredera cordifolia (tenore) steen) gel in the management of diabetic wound healing in aloxan-induced rat models | |
| CN116159018A (zh) | 一种新型外用溴莫尼定凝胶剂 | |
| EP3677264A1 (en) | Composition for preventing or treating atopic dermatitis | |
| US10322142B2 (en) | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof | |
| CN113713000B (zh) | 用于治疗疮痈、烧烫伤和痤疮的主药成分组合物、缓控释药物制剂及其制备方法和应用 | |
| RU2785542C2 (ru) | Композиция для комплексного ухода за кожей при лечении дерматозов | |
| Sandhya et al. | Evaluation of a dermatological herbal hydrogel integrated with Ipomea pes-tigridis for anti acne activity | |
| Tadeg et al. | Performance evaluation of topical formulations of the crude extracts of L. adoensis and O. rochetiana | |
| CN117427006A (zh) | 包含青蒿提取物和油溶性成分的组合物及其应用 | |
| WO2023172216A1 (en) | Hydrocortisone and pramoxine topical formulations having enhanced in-vitro release | |
| CN117338717A (zh) | 一种黄芩素外用制剂及其在特应性皮炎治疗中的应用 | |
| CN117298034A (zh) | 一种治疗儿童湿疹的载药微乳-纳米凝胶复合制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |